Richard joined the MHRA as a GMP Inspector in 2001 and is currently a Unit Manager with responsibility for the GMP and GPvP Inspection teams. Prior to joining the MHRA Richard worked in the pharmaceutical industry for over 17 years focusing mainly on the manufacture of bulk active pharmaceutical ingredients. He has experience of process development and technical support and has held managerial positions in both QA and production. Whilst at the MHRA, in addition to the inspection of a wide range of pharmaceutical manufacturers, Richard has been an Operations Manager with responsibility for teams of both GMP and GDP Inspectors and has most recently been part of the Agency team responsible for implementing the changes arising from the Falsified Medicines Directive.

Claire joined the agency as a GDP Inspector in January 2013 and has a background in pharmaceutical manufacturing and auditing of 15 years. Aspects of previous roles in a large pharmaceutical company include project management, QMS implementation and Quality Assurance. She is PRINCE2 qualified and has a degree in Business.

Peter joined the MHRA in 1993, having spent the previous three years with the Department of Health and NHS Management Executive in Leeds. Peter initially worked in the Enforcement Group and was responsible for conducting a two-year project into the use of Traditional Chinese Medicines in the UK before managing the unit's criminal prosecution team. Peter joined the GDP Inspectorate in June 2002 and became an Operations Manager in November 2011 and a Senior Inspector in 2016. Peter currently leads one of the GDP Inspectorates two operational teams and combines this role with being a member of the GDP Inspectorates Senior Inspector Group.

Jacqui joined the GDP Inspectorate in April 2011 and is responsible for inspecting the full range of UK distribution companies nationwide.  Jacqui holds a degree in Pharmacology and prior to joining the MHRA GDP Inspectorate, Jacqui worked in the MHRA Licensing Division as a Scientific Assessor.  Jacqui acted briefly as GDP Operations Manager in 2017. Jacqui enjoys contributing to inspector development and stakeholder engagement; currently involved in NHS Project work.

Claire joined the agency as a GDP Inspector in January 2013 and has a background in pharmaceutical manufacturing and auditing of 15 years. Aspects of previous roles in a large pharmaceutical company include project management, QMS implementation and Quality Assurance. She is PRINCE2 qualified and has a degree in Business.

Madeleine is a senior GDP inspector and joined the MHRA in August 2009. Her previous experience includes NHS pharmacy manufacturing, project management in NHS Blood and Transplant and some teaching within the NHS. Recent projects include working with Cogent to develop the RP Gold Standard and working with the Maritime and Coastguard Agency to improve compliance within the marine sector. Madeleine enjoys contributing to inspector development and inspection consistency. Madeleine is registered with the General Pharmaceutical Council.

Naseem has been with the MHRA since 2006 and is an Intelligence Analyst in the Enforcement Groups Intelligence Unit. In 2006 Naseem completed the Covert Internet Investigators course run by the National Centre for Policing Excellence. He is currently the Enforcement Group’s Covert Internet Investigator and responsible for the conduct of internet investigations and covert internet test purchases. Naseem has also completed the Initial Analytical Techniques Course run by the National Policing Improvement Agency. Before Joining the MHRA in 2005, he completed an LLB (Hons) and MA in Intelligence & International Security.

Phil joined the MHRA in the Pharmacovigilance Inspectorate in July 2009. In 2010 he moved to the GDP Inspectorate, where he became a GDP Operations Manager in 2013. He is a pharmacist by profession, who initially worked in the pharmaceutical industry for over 30 years, for 4 different global pharmaceutical companies. His positions included different managerial and project leader roles at all stages of pharmaceutical development. Phil currently manages one of the GDP Inspectorates two operational teams.

Tony was a founder member of the GDP Inspectorate when it was created in 2001 and is a Senior GDP Inspector responsible for inspecting the full range of UK distribution companies. He is a member of the PIC/S GDP working group, working on the training and aligning of GDP standards for PIC/S member countries. He was part of the EMA GDP drafting group preparing the GDP Guidelines and updates to the compilation of community procedures and involved in training the GMDP inspectors on the new guidelines. He was also a member of the team who reviewed the UK supply chain and looked at ways to improve the standard of the Wholesale Dealer 'Responsible Person'. He is currently a member of the implementation team for the Falsified Medicines Directive and working on developing the new Risk Based Inspection IT system for the MHRA. Tony has been with the MHRA for 24 years, working initially with the MHRA Enforcement Group where he was a Senior Investigation Officer. As such he was responsible for investigating counterfeit medicines, internet sales and other illegal activity with pharmaceuticals.

Terry is an Inspector within the GDP Inspectorate at the Medicines and Healthcare products Regulatory Agency (MHRA). He joined the Agency in 2009 having previously worked over 25 years in a variety of pharmaceutical industry technical and managerial roles within R&D and QA.

Cheryl joined the MHRA as a GDP inspector in 2005. Cheryl is a Chartered Chemist and spent many years working within industry as a research chemist during which time she filed a number of patents both European and Worldwide. She has extensive experience working within Project and Programme Management roles with responsibility for a wide range of projects spanning various scientific and engineering disciplines. As well a performing a full range of GDP inspections nationwide, Cheryl was the MHRA representative on the GDP drafting Group at the EMA. Since the current guidance has been implemented, Cheryl has been leading the project to raise awareness within the medicines supply chain that companies and sites not previously regulated are impacted by the change in legislation.

Peter is a pharmacist by profession and joined the MHRA in January 2013.

Prior to joining the MHRA, Peter had worked in the pharmaceutical industry for over 30 years, focusing mainly on Pharmaceutical Wholesale and Retail Pharmacy.in various managerial roles including Operations Management, Regulatory Affairs, Quality Assurance and acted as Responsible Person for a number of companies in the UK.

He was an industry representative on the HDA UK (BAPW) RP Committee, was instrumental in identifying some of the more recent examples of falsified medicines and is a member of the MHRA Falsified Medical Product Stakeholders Group.

More recently he has been involved in a number of meetings and working groups involved in the implementation of the Falsified Medicines Directive in the UK.

Bernadette is a GDP Inspector and joined the MHRA in March 2005.  Her previous experience includes local government enforcement duties within a Trading Standards environment.  Bernadette spent 10 years working as an Investigator within the MHRA Enforcement and Intelligence division dealing with criminal investigations.  She has played an important role in the year on year success of the MHRA’s Operation Pangea which focuses on the illegal internet trade of medicines and medical devices globally.  In 2015, £15.8 million worth of fake medicines and devices were seized during UK operations.  Bernadette is an accredited Counter Fraud Specialist.

More information coming soon.

More information coming soon.

More information coming soon.